Fusion protein based on Grb2-SH2 domain for cancer therapy

详细信息    查看全文

• 作者：Yuriko Saito ; Takako Furukawa ; Yasushi Arano ; Yasuhisa Fujibayashi ; Tsuneo Saga
• 关键词：EGFR ; SH2 domain ; Grb2 ; Cancer therapy
• 刊名：Biochemical and Biophysical Research Communications
• 出版年：2010
• 出版时间：20 August 2010
• 年：2010
• 卷：399
• 期：2
• 页码：262-267
• 全文大小：558 K

文摘

Epidermal growth factor receptor (EGFR) is one of the very attractive targets for cancer therapy. In this study, we generated fusion proteins containing one or two Src-homology 2 (SH2) domains of growth factor receptor bound protein 2 (Grb2), which bind to phosphorylated EGFR, added with HIV-1 transactivating transcription for cell membrane penetration (termed TSF and TSSF, respectively). We examined if they can interfere Grb2-mediated signaling pathway and suppress tumor growth as expected from the lack of SH3 domain, which is necessary to intermediate EGFR–Grb2 cell signaling, in the fusion proteins. The transduction efficiency of TSSF was similar to that of TSF, but the binding activity of TSSF to EGFR was higher than that of TSF. Treatment of EGFR-overexpressing cells showed that TSSF decreased p42-ERK phosphorylation, while TSF did not. Both the proteins delayed cell growth but did not induce cell death in culture. TSSF also significantly suppressed tumor growth in vivo under consecutive administration. In conclusion, TSSF showed an ability to inhibit EGFR–Grb2 signaling and could have a potential to treat EGFR-activated cancer.